Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting (November 10-14)

On October 1, 2021, Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that three posters featuring preclinical data from the company’s engEx™ Platform programs will be presented during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), which is being held virtually and in person in Washington, DC, from November 10-14, 2021. In addition, Codiak’s Chief Scientific Officer, Sriram Sathyanarayanan, PhD, will co-chair a session entitled “Exosomes and Cellular Engineering” and present on the company’s approach to developing engineered exosome therapeutics and the opportunity to overcome historical challenges of other modalities in immuno-oncology.   

Login Or Register To Read Full Story